Home » Stocks » Inhibrx

Inhibrx, Inc. (INBX)

Stock Price: $17.23 USD -1.20 (-6.51%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 649.74M
Revenue (ttm) 5.69M
Net Income (ttm) -74.45M
Shares Out 37.71M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $17.23
Previous Close $18.43
Change ($) -1.20
Change (%) -6.51%
Day's Open 18.23
Day's Range 17.00 - 18.68
Day's Volume 55,728
52-Week Range 15.76 - 26.98

More Stats

Market Cap 649.74M
Enterprise Value 699.55M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 37.71M
Float 22.20M
EPS (basic) n/a
EPS (diluted) -2.09
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 212,066
Short Ratio 0.41
Short % of Float 0.90%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 114.13
PB Ratio n/a
Revenue 5.69M
Operating Income n/a
Net Income -74.45M
Free Cash Flow n/a
Net Cash -49.81M
Net Cash / Share -1.32
Gross Margin -609.45%
Operating Margin n/a
Profit Margin -1,307.68%
FCF Margin n/a
ROA -109.80%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(65.41% upside)
Current: $17.23
Target: 28.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth53.71%-
Gross Profit13.218.60
Operating Income-43.71-29.51
Net Income-51.40-31.16
Shares Outstanding18.1518.15
Earnings Per Share-2.83-1.72
Operating Cash Flow-32.08-23.09
Capital Expenditures-1.81-1.43
Free Cash Flow-33.89-24.52
Cash & Equivalents11.542.10
Total Debt41.739.49
Net Cash / Debt-30.19-7.39
Book Value-93.57-57.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inhibrx, Inc.
Country United States
Employees 75
CEO Mark P. Lappe

Stock Information

Ticker Symbol INBX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INBX
IPO Date August 19, 2020


Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037